Antibody responses to inactivated and mRNA SARS-CoV-2 vaccines in familial Mediterranean fever patients treated with interleukin-1 inhibitors

Dear Editor, During the coronavirus disease 2019 (COVID-19) pandemic, the disease course of COVID-19 and vaccine responses in patients with autoinflammatory diseases have been among the topics of interest in rheumatology. Familial Mediterranean fever (FMF) is the most common monogenic autoinflammatory disease and some studies have been published regarding the relationship between FMF and COVID-19. The incidence or severity of COVID-19 in FMF patients was not found to be different from that of the non-FMF population [1]. There are data regarding the safety of COVID-19 vaccines in patients with autoinflammatory disorders taking biologics [2], yet there are not enough data regarding the antibody responses to the vaccines. We therefore measured the antibody responses of FMF patients on IL-1 inhibitors who were vaccinated with CoronaVac (Sinovac Biotech, Beijing, China) or BNT162b2 (Pfizer-BioNTech). Study participants consisted of FMF patients who were followed up in our rheumatology clinic....